共 49 条
[21]
O’Hara MH(2014)CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors Cancer Cell 26 136-5747
[22]
Heilmann AM(2016)Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Lancet Oncol. 17 425-281
[23]
Vora SR(2016)Practical issues in the application of p16 immunohistochemistry in diagnostic pathology Hum. Pathol. 51 64-835
[24]
Cristofanilli M(2013)CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry Neuropathology 33 405-5705
[25]
Mahajan A(2017)Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas J. Clin. Oncol. 35 4500-201
[26]
Purkait S(2014)Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome Int. J. Cancer 135 887-177
[27]
Lerner SP(2005)Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype Clin. Cancer Res. 11 5740-52
[28]
Lim AM(2001)Hypermethylationofp16(INK4a) and p15(INK4b) genes in non-small cell lung cancer Int. J. Oncol. 19 277-undefined
[29]
Chapman EJ(2005)Alterations of tumour suppressor gene p16INK4a in pancreatic ductal carcinoma Bmc Gastroenterol. 5 22-undefined
[30]
Harnden P(2013)Technical and implementation issues in using next-generation sequencing of cancers in clinical practice Br. J. Cancer 109 827-undefined